Abbisko Cayman Limited (HK:2256) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, is set to present promising phase 2 study results of its drug pimicotinib at the upcoming American Society of Hematology Annual Conference. The study focuses on pimicotinib’s potential in treating chronic graft-versus-host disease in patients unresponsive to previous treatments. Investors are advised to stay informed as the company explores new therapeutic avenues.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.